Bladder Cancer Coverage from Every Angle

Enrique Grande, MD, PhD, on Results From IMvigor130: Atezolizumab Plus Platinum-Based Chemotherapy for Urothelial Cancer

Posted: Friday, April 16, 2021

Enrique Grande, MD, PhD, of The University of Texas MD Anderson Cancer Center, Madrid, discusses results from the IMvigor130 trial and what they could mean for patients with previously untreated metastatic urothelial carcinoma, especially in terms of overall survival, added toxicity, and duration of therapy.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.